DNTH vs RTX · rev $6.2M vs P/E 36, rev $88.60B
Dianthus Therapeutics Inc. (DNTH) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
DNTH currently screens at market cap $4.40B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the DNTH and RTX stock pages for the full models.
Not investment advice.